Endeavor BioMedicines
Private Company
Total funding raised: $296M
Overview
Endeavor BioMedicines is a private, clinical-stage biotech advancing taladegib (ENV-101), a Hedgehog signaling pathway inhibitor, for the treatment of idiopathic pulmonary fibrosis (IPF). The company has generated promising Phase 2a data showing improved lung function and potential disease reversal, leading to the receipt of PRIME designation from the European Medicines Agency in late 2025. Endeavor is now advancing a Phase 2b trial (WHISTLE-PF), with enrollment completion targeted for the first half of 2026, positioning the asset as a potential disease-modifying therapy in a high-need area.
Technology Platform
Small molecule inhibition of the Hedgehog (Hh) signaling pathway to target the root cause of fibrosis.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
The IPF market includes approved anti-fibrotics pirfenidone and nintedanib, which slow decline but do not reverse disease. Several other companies are developing novel therapies targeting various pathways. Taladegib's unique mechanism (Hedgehog inhibition) and early reversal data position it competitively, but it must demonstrate superiority or best-in-class profile in later-stage trials.